ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the National Comprehensive ...
ImmunityBio has achieved a significant milestone beyond its already approved drug, ANKTIVA. On March 13, 2026, the biotechnology firm announced the successful validation of a scalable manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results